Related Experiment Videos
A practical cost analysis of bivalirudin
1Saint Joseph's Hospital of Atlanta, Georgia 30342, USA. acompton@sjha.org
Insights
Bivalirudin effectively reduces both bleeding and ischemic complications during percutaneous coronary intervention (PCI). Its use is cost-effective, offsetting its own expense by lowering overall medical costs associated with these complications.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Percutaneous coronary intervention (PCI) carries significant risks of ischemic and bleeding complications.
- These complications lead to increased morbidity, mortality, and healthcare costs.
Purpose of the Study:
- To evaluate the effectiveness and cost-efficiency of bivalirudin in mitigating PCI-related complications.
- To assess the economic impact of bivalirudin on total medical costs.
Main Methods:
- Analysis of data from three clinical trials involving bivalirudin.
- Calculation of the number needed to treat (NNT) to avoid bleeding complications using data from the Bivalirudin Angioplasty Trial.
Main Results:
- Bivalirudin is the only antithrombotic agent demonstrated to reduce both ischemic and hemorrhagic complications in PCI.
- Cost models indicate that bivalirudin usage offsets its own cost through complication reduction.
Conclusions:
- Bivalirudin offers a dual benefit of reducing both ischemic and bleeding risks in PCI.
- The use of bivalirudin is economically advantageous, lowering overall healthcare expenditures related to PCI complications.
Abstract:
Despite advances in percutaneous coronary intervention (PCI) techniques and adjunctive therapies, the risks of ischemic and bleeding complications with PCI remain significant. These complications are associated with significant morbidity and mortality, as well as substantially higher costs. Bivalirudin is the only antithrombotic agent that has been shown to reduce both ischemic and hemorrhagic complications associated with PCI. Cost models drawn from the results of three clinical trials of bivalirudin have estimated its potential impact on total medical costs. In addition, the number needed to treat to avoid a bleeding complication has been calculated based on patients shown to have a heightened risk of bleeding in the Bivalirudin Angioplasty Trial. In all models assessed, the use of bivalirudin offset most of its own cost through reductions in bleeding and ischemic complications.